Literature DB >> 25318949

CD5- and CD23-positive splenic diffuse large B-cell lymphoma with very low CD20 expression.

Rie Tabata1, Hideaki Iwama, Chiharu Tabata, Ryoji Yasumizu, Masaru Kojima.   

Abstract

We report a rare primary splenic diffuse large B-cell lymphoma demonstrating CD5(+) and CD23(+) with very low CD20 expression. The only lesion was detected in the spleen, which was extremely enlarged with multiple large white-colored nodules. The lesion was characterized by a diffuse growth pattern of medium- to large-sized lymphoma cells with abundant cytoplasm. Immunohistochemical and flow cytometric study demonstrated that the lymphoma cells were negative for CD2, CD3, CD4, CD8, CD10, CD56, CD138, ALK-1, λ-light chain, and cyclin-D1, and positive for CD5, CD19, CD23, CD25, CD38, CD43, CD79a, IgM, IgD, κ-light chain, BCL2, BCL6, BOB. 1, Oct-2, Pax5, and MUM-1. CD20 was very weakly positive immunohistochemically, and negative by flow cytometric analysis. These findings resembled Richter syndrome, although chronic lymphocytic leukemia was not preexisting. Extremely poor outcome might be supposed because the effect of rituximab might be quite limited since CD20 was very weakly positive, in addition to an inferior prognosis of both CD20(-) and CD5(+) diffuse large B-cell lymphoma. Careful management is thus necessary.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25318949     DOI: 10.3960/jslrt.54.155

Source DB:  PubMed          Journal:  J Clin Exp Hematop        ISSN: 1346-4280


  4 in total

1.  Immunoglobulin E induces colon cancer cell apoptosis via enhancing cyp27b1 expression.

Authors:  Zhen-Shi Ye; Li-Na Fan; Lin Wang; Bin Yang; Li-Feng Wang; Yuan-Sheng Liu; Su-Na Ji; Hong-Zhi Xu; Chuan-Xing Xiao
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

Review 2.  Targeted Radionuclide Therapy of Human Tumors.

Authors:  Sergey V Gudkov; Natalya Yu Shilyagina; Vladimir A Vodeneev; Andrei V Zvyagin
Journal:  Int J Mol Sci       Date:  2015-12-28       Impact factor: 5.923

3.  Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report.

Authors:  Wen-Ying Zhang; Yao Wang; Ye-Lei Guo; Han-Ren Dai; Qing-Ming Yang; Ya-Jing Zhang; Yan Zhang; Mei-Xia Chen; Chun-Meng Wang; Kai-Chao Feng; Su-Xia Li; Yang Liu; Feng-Xia Shi; Can Luo; Wei-Dong Han
Journal:  Signal Transduct Target Ther       Date:  2016-03-11

4.  Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.

Authors:  Lorenz Jahn; Dirk M van der Steen; Renate S Hagedoorn; Pleun Hombrink; Michel G D Kester; Marjolein P Schoonakker; Daniëlle de Ridder; Peter A van Veelen; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Oncotarget       Date:  2016-11-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.